Features of mometasone furoate nasal spray and its utility in the management of allergic rhinitis.
Mometasone furoate aqueous nasal spray (NS; Nasonex, Schering Corporation), is a synthetic corticosteroid approved for the prophylaxis and treatment of seasonal allergic rhinitis (SAR) and the treatment of perennial allergic rhinitis (PAR) in patients >or= 12 years of age, and for the treatment of SAR and PAR in children as young as 2 years of age. Studies demonstrate that mometasone furoate NS is a potent, clinically effective and well-tolerated intranasal corticosteroid with negligible systemic activity and which offers the convenience of once-daily dosing.
Schenkel
Eric
E
Valley Allergy and Asthma Treatment Center/Valley Clinical Research Center, Easton, PA, USA. Eschenkelm@aol.com
D000281:Administration, Intranasal; D018926:Anti-Allergic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D005938:Glucocorticoids; D006801:Humans; D000068656:Mometasone Furoate; D011244:Pregnadienediols / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy* / Q000517:prevention & control; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy* / Q000517:prevention & control; D012852:Sinusitis / Q000188:drug therapy
D018926:Anti-Allergic Agents; D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D011244:Pregnadienediols; D000068656:Mometasone Furoate